Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628210 · ClinicalTrials.gov registry record · NA
Interbody Spacers With map3® Cellular Allogeneic Bone Graft in Anterior or Lateral Lumbar Interbody Fusion
A NA study of Degenerative Disc Disease and Spondylolisthesis, sponsored by RTI Surgical.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT02628210: Completed NA study of Degenerative Disc Disease and Spondylolisthesis, sponsored by RTI Surgical.
NCT02628210 is a NA study of Degenerative Disc Disease and Spondylolisthesis that has completed, run by RTI Surgical. The registered enrollment target is 30 participants, below the 168-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02628210, a NA study of Degenerative Disc Disease and Spondylolisthesis, has completed, sponsored by RTI Surgical.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a single-arm post-market study in patients requiring lumbar fusion using allograft interbody spacer in conjunction with map3® Cellular Allogeneic Bone Graft in patients with degenerative disc disease (DDD). This cohort study will enroll 80 patients total at up to 10 sites. After subjects have signed an informed consent, the baseline visit and examinations will be completed. Patients will be evaluated at 6 weeks, 3 months, 6 months, 12 months, and 24 month visit after surgery.
Conditions Studied
Interventions
- OTHER map3® Cellular Allogeneic Bone Graft
Study Locations (3)
New York
- Spine Surgery of Buffalo Niagara, LLC - Niagara Falls
- AXIS Neurosurgery and Spine of WNY, PLLC - Williamsville
Ohio
- Carl & Edyth Lindner Center for Research The Christ Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-02 |
| Est. Completion | 2020-06 |
| Phase | NA |
What the finished NCT02628210 record still lists
NCT02628210 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 168-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Degenerative Disc Disease appearing as the primary indexed condition, and to 1 intervention - of which map3® Cellular Allogeneic Bone Graft is the first listed.
NCT02628210 reports a single indexed study location in New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT02628210 about?
NCT02628210 is a clinical study titled "Interbody Spacers With map3® Cellular Allogeneic Bone Graft in Anterior or Lateral Lumbar Interbody Fusion". This is a single-arm post-market study in patients requiring lumbar fusion using allograft interbody spacer in conjunction with map3® Cellular Allogeneic Bone Graft in patients with degenerative disc disease (DDD). This cohort study will enroll 80 patients total at up to 10 sites. After subjects hav...
What is the current status of trial NCT02628210?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-02. Estimated completion is 2020-06.
What conditions does trial NCT02628210 study?
This clinical trial studies the following conditions: Degenerative Disc Disease, Spondylolisthesis, Spondylosis.
What interventions are being tested in trial NCT02628210?
The interventions under investigation include: map3® Cellular Allogeneic Bone Graft (OTHER).
Who is sponsoring clinical trial NCT02628210?
This trial is sponsored by RTI Surgical, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02628210 being conducted?
This trial has 3 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Degenerative Disc Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02628210's enrollment target sits among peer trials
30 39th of 42 higher than 4 of 42 other Degenerative Disc Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Degenerative Disc Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigation of DEXA-C Anterior Cervical Interbody System
RECRUITING · NA
-
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
RECRUITING · NA
-
Trial for Treating Painful Degenerative Disc Disease
RECRUITING · NA
-
Evaluation of Safety and Effectiveness of Primary Hybrid Construct of Mobi-C and ACDF in the Treatment of Two-level Symptomatic Degenerative Disc Disease in the Cervical Spine.
RECRUITING · NA
-
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
RECRUITING · NA
-
ACDF Using Structural Allograft vs. Tritanium C
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia